Aerie Pharmaceuticals (AERI) Given a $73.00 Price Target at Canaccord Genuity
Other analysts have also issued research reports about the company. Cantor Fitzgerald set a $77.00 target price on Aerie Pharmaceuticals and gave the company a buy rating in a report on Monday. Needham & Company LLC reaffirmed a buy rating and issued a $76.00 target price (up previously from $65.00) on shares of Aerie Pharmaceuticals in a report on Monday, October 16th. Mizuho reaffirmed a buy rating and issued a $70.00 target price on shares of Aerie Pharmaceuticals in a report on Monday, October 16th. JMP Securities set a $68.00 target price on Aerie Pharmaceuticals and gave the company a buy rating in a report on Wednesday, October 11th. Finally, Cowen reaffirmed a buy rating on shares of Aerie Pharmaceuticals in a report on Thursday, October 5th. One research analyst has rated the stock with a sell rating, two have given a hold rating and thirteen have assigned a buy rating to the company. Aerie Pharmaceuticals currently has a consensus rating of Buy and an average target price of $72.00.
Shares of Aerie Pharmaceuticals (AERI) opened at $58.30 on Monday. The company has a debt-to-equity ratio of 0.78, a current ratio of 15.24 and a quick ratio of 15.24. Aerie Pharmaceuticals has a fifty-two week low of $35.50 and a fifty-two week high of $66.60.
Aerie Pharmaceuticals Company Profile
Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).
Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.